TRL 7
EP21382524
PCT/EP2022/066014
Youcef Azeli, MD, PhD; Eduard Llobet, PhD; Albert Fernandez, PhD
Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.
Viral respiratory infections have been, are and will always be present in our lives. The early detection of symptoms and rapid tests are the basis of an efficient screening strategy to control the transmission of these.
Our research group has managed to develop a unique mass screening of respiratory viral infections based on artificial intelligence based on the symptoms and the recognition of the aroma of a hydroalcoholic gel that has a high sensitivity (97%). A prospective study has been carried out for the development and validation of this technology and the European patent has recently been obtained. The regulatory procedures have been explored and we are waiting for companies willing to invest in a screening system useful in work environments to minimize the economic effect of layoffs and in vulnerable environments such as nursing homes to mitigate the effect of epidemic outbreaks of viral infections on the healthcare system.
Easy implementation
Low cost
Easy distribution in all the world
No cost of development
No adverse effects
Available in the market in 1 month
Mass screening tool
IISPV & URV
